Warm Autoimmune Hemolytic Anemia (wAIHA) research hub
3 indexed studies · 0 currently recruiting
- active not recruitingPHASE3
A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia
This study looks at a new medicine, ianalumab, for people with warm autoimmune hemolytic anemia (wAIHA) who haven't responded to previous treatments. It aims to see if ianalumab can increase healthy red blood cells and if it is safe.
United States · Argentina · Australia - active not recruitingPHASE2
Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA)
This study is looking into a new medication called rilzabrutinib for adults in the UK with warm autoimmune hemolytic anemia (wAIHA). It will check if the treatment is safe, how well it works, and how the body handles it. Participants will take the medication by mouth.
United States · Austria · China - authorisedTherapeutic exploratory (Phase II)
Exploratory Study of Ianalumab in Adults with Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) who Have Previously Benefited from Ianalumab (VAY RE-HIT)
This study looks at a medicine called ianalumab for adults with certain blood conditions (ITP or wAIHA). It wants to see if the medicine continues to work well for those who have used it before, aiming to understand its long-term benefits.
Germany · Czechia · Belgium